Experts have warned that vaccines that are not properly tested can cause harm in many ways - from a negative impact on health to creating a false sense of security or undermining trust in vaccinations.
She says she is cautiously optimistic that will happen soon but says safety will not be compromised to get there.
President Rodrigo Duterte earlier thanked and accepted the offer of Russian Federation to supply the Philippines with COVID-19 vaccines, adding he hopes for a COVID-free Christmas celebration in the country.
Her deputy, Dr. Howard Njoo, says the Russian product went from discovery to approval unusually fast. Russian Federation skipped, for example, Phase 3 testing trials, which involve inoculation of thousands of test participants to examine them for possible side effects and efficacy before going to the public.
Phase 3 trials usually involve thousands of people and last for months, according to the World Health Organization (WHO). These trials are separated into phases, with Phase III data being required by the US Food and Drug Administration (FDA) for vaccine approval and dissemination.
"Not every vaccine is 100 per cent safe, for example in some instances, people who are immunocompromised or, you know, extremely young or extremely old", Professor Purcell said.
He told ANI that if the Russian vaccine is successful, then it would have to be seen critically whether it is safe and effective.
The 20.4% quarter-on-quarter drop in the April to June period is worse than anything since records began in 1955, the Office for National Statistics said.
"This particular vaccine would find it extremely hard to find an approved deployment in Australia", Professor Purcell said.
At the same time, Russian Federation allowing a vaccine developed by Moscow's Gamaleya Institute for civilian use even before clinical trials are completed has triggered safety warnings from pharmaceutical companies.
In Berlin, a spokesman for the German health ministry told newspaper group RND that "there is no known data on the quality, efficacy and safety of the Russian vaccine", adding that "patient safety is of the highest priority". But there is no definite cure for Covid-19 yet.
"Even in the US and other jurisdictions, there are methods about our emergency use authorisations that can also shortcut wider deployment of vaccines so it's all about the risk versus benefit".
The vaccine was developed by Moscow's Gamaleya Institute after less than two months of human testing, Reuters reports. The numbers presented by them in terms of trials and testing are too few.
"Only after that review, having access in a transparent way to those data and all the information, are we going to take a position", he said. But scientists within Russian Federation and overseas have voiced skepticism, questioning the decision to register the vaccine before Phase 3 trials have been completed.
Even looking at the antibody response "isn't enough" to declare a vaccine to be ready for public use, the CEO said.